Pneumococcal Vaccination Rates in Adults in Germany: an Analysis of Statutory Health Insurance Data on More Than 850,000 Individuals

Overview

Journal Dtsch Arztebl Int

Specialties General Medicine
Public Health

Date 2013 Nov 28

PMID 24280430

Citations 20

Authors

Ulrike Theidel

Alexander Kuhlmann

Anja Braem

Affiliations

Soon will be listed here.

Abstract

Background: The German Standing Committee on Vaccination Recommendations (Ständige Impfkommission, STIKO) recommends standard vaccination against pneumococcal infections for all persons aged 60 or older, and for all persons of any age with an increased health risk. It is not known how many persons in the target group in Germany have actually been vaccinated.

Method: We used claims data of a German statutory health insurance (Deutsche BKK) to determine pneumococcal vaccination rates, stratified by age and risk, for the one-year period 1 July 2008 to 30 June 2009. The number of influenza vaccinations in the same period was analyzed for comparison. Because pneumococcal vaccination does not need to be performed annually, the calculated rates are an underestimate of the percentage of persons who have been vaccinated. A simulation model was used to correct for persons vaccinated at earlier times. The vaccination rates were estimated on the basis of various scenarios.

Results: Data were obtained on 867 683 persons aged 18 or older. According to an optimistic estimate, the percentage of pneumococcal vaccination in the overall population is 3.75% for persons aged 18-59 and 50.89% for persons aged 60 and above (influenza: 8.80% and 41.15%, respectively). In persons at elevated risk, the rate of vaccination in the presence of at least one risk factor is 12.66% / 54.67% (influenza: 15.66% / 39.96%). In persons with moderate risk, the vaccination rate is 16.02% / 56.75% (influenza: 18.54% / 40.61%); in persons whose elevated risk was high, it is 8.93% / 52.21% (influenza: 7.37%/37.78%). The limitations of this study are the short study period and the inability to define the population at risk unambiguously.

Conclusion: The rate of pneumococcal vaccination in adults in Germany is too low; at best, it is comparable to that of influenza vaccination. These results should be validated by nationwide monitoring of the pneumococcal vaccination program. For example, questions about pneumococcal vaccination could be included in the GEDA study (German Health Update) that is conducted annually by the Robert Koch Institute.

Citing Articles

Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany.

Deb A, Podmore B, Barnett R, Beier D, Galetzka W, Qizilbash N Epidemiol Infect. 2022; 150:e204.

PMID: 36345842 PMC: 9987016. DOI: 10.1017/S0950268822001182.

Pneumococcal vaccination coverage in individuals (16-59 years) with a newly diagnosed risk condition in Germany.

Deb A, Podmore B, Barnett R, Beier D, Galetzka W, Qizilbash N BMC Infect Dis. 2022; 22(1):753.

PMID: 36171549 PMC: 9517976. DOI: 10.1186/s12879-022-07736-1.

Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso.

Wellmann P, Kromer C, Siemer R, Klein S, Mohr J, Lippert U Vaccines (Basel). 2022; 10(7).

PMID: 35891172 PMC: 9315583. DOI: 10.3390/vaccines10071005.

Pneumococcal vaccination rates in immunocompromised patients in Germany: A retrospective cohort study to assess sequential vaccination rates and changes over time.

Sprenger R, Hackl D, Kossack N, Schiffner-Rohe J, Wohlleben J, von Eiff C PLoS One. 2022; 17(3):e0265433.

PMID: 35316288 PMC: 8939779. DOI: 10.1371/journal.pone.0265433.

Pneumococcal Vaccination Coverage and Uptake Among Adults in Switzerland: A Nationwide Cross-Sectional Study of Vaccination Records.

Zens K, Baroutsou V, Fehr J, Lang P Front Public Health. 2022; 9:759602.

PMID: 35174130 PMC: 8841552. DOI: 10.3389/fpubh.2021.759602.

References

Musher D . Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis. 1992; 14(4):801-7. DOI: 10.1093/clinids/14.4.801. View

Pletz M, von Baum H, van der Linden M, Rohde G, Schutte H, Suttorp N . The burden of pneumococcal pneumonia - experience of the German competence network CAPNETZ. Pneumologie. 2012; 66(8):470-5. DOI: 10.1055/s-0032-1310103. View

Welte T, Torres A, Nathwani D . Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2010; 67(1):71-9. DOI: 10.1136/thx.2009.129502. View

Giersiepen K, Pohlabeln H, Egidi G, Pigeot I . [Quality of diagnostic ICD coding for outpatients in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007; 50(8):1028-38. DOI: 10.1007/s00103-007-0297-4. View

Maruyama T, Taguchi O, Niederman M, Morser J, Kobayashi H, Kobayashi T . Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010; 340:c1004. PMC: 2834887. DOI: 10.1136/bmj.c1004. View

Moberley S, Holden J, Tatham D, Andrews R . Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008; (1):CD000422. DOI: 10.1002/14651858.CD000422.pub2. View

Ogilvie I, Khoury A, Cui Y, Dasbach E, Grabenstein J, Goetghebeur M . Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009; 27(36):4891-904. DOI: 10.1016/j.vaccine.2009.05.061. View

de Roux A, Schmole-Thoma B, Schmoele-Thoma B, Siber G, Hackell J, Kuhnke A . Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008; 46(7):1015-23. DOI: 10.1086/529142. View

Christenson B, Pauksen K, Sylvan S . Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J. 2008; 5:52. PMC: 2390520. DOI: 10.1186/1743-422X-5-52. View

10.

Brenner G, Koch H, Kerek-Bodden H, Heuer J, Lang A . [Diagnoses as the subject of health service research to analyse the morbidity of outpatients]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007; 50(8):1021-7. DOI: 10.1007/s00103-007-0295-6. View

11.

Kuhlmann A, Theidel U, Pletz M, von der Schulenburg J . Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev. 2012; 2(1):4. PMC: 3463422. DOI: 10.1186/2191-1991-2-4. View

12.

Schubert I, Ihle P, Koster I . [Internal confirmation of diagnoses in routine statutory health insurance data: concept with examples and case definitions]. Gesundheitswesen. 2010; 72(6):316-22. DOI: 10.1055/s-0030-1249688. View

13.

Ludwig E . [Pneumococcal infections -- clinical features, prevention and current therapy. Interview with Dr. Endre Ludwig by Anna Radnai]. Orv Hetil. 2013; 154(3):118-20. DOI: 10.1556/OH.2013.3M. View

14.

Fleming D, Elliot A . Estimating the risk population in relation to influenza vaccination policy. Vaccine. 2006; 24(20):4378-85. DOI: 10.1016/j.vaccine.2006.02.053. View

15.

Meyer C, Wiese-Posselt M, Delere Y, Reiter S, Koch Institute , Standigen Impfkommission am Robert Koch-Institut . [Recommendations of the Vaccine Standards Commission of the Robert Koch Institute]. Pharm Unserer Zeit. 2007; 37(1):54-62. DOI: 10.1002/pauz.200700251. View

16.

Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H . New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009; 64(12):1062-9. PMC: 2782114. DOI: 10.1136/thx.2008.109785. View

17.

Damm K, Schubert J, von der Schulenburg J . Promoting vaccinations - an analysis of measures taken by German statutory health insurers. Health Econ Rev. 2012; 1(1):16. PMC: 3402966. DOI: 10.1186/2191-1991-1-16. View

18.

Ruckinger S, van der Linden M, Reinert R, von Kries R, Burckhardt F, Siedler A . Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009; 27(31):4136-41. DOI: 10.1016/j.vaccine.2009.04.057. View

19.

Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A . The remaining challenges of pneumococcal disease in adults. Eur Respir Rev. 2012; 21(123):57-65. PMC: 9487474. DOI: 10.1183/09059180.00008911. View